prednisolone for 28 days

ApprovedSmall molecule

prednisolone for 28 days is one of 6 small molecule programs targeting Esophageal stricture. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal StrictureActive, not recruiting

Esophageal StrictureApproved

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Esophageal Stricture

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Approved

2 2

Kenalog

BBassett Healthcare

Approved

—3

Decadron

AAspen Global Incorporated

Phase 2

1 4

Pulmicort

SSalix

Phase 2

1 5

prednisolone for 28 days

EE-DA Hospital

Approved

1 6

Tranilast

NNuon Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Esophageal stricture1 trial

Oral Prednisolone to Prevent Esophageal Stricture After RFA for Long-segment Esophageal Neoplasia

Unknown status·—·Phase 4·NCT05768282·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for prednisolone for 28 days. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — prednisolone for 28 days compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for prednisolone for 28 days. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — E-DA Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: EE-DA Hospital

prednisolone for 28 days

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Esophageal stricture1 trial

References

Drug Info

Quick Facts

Related News